PBC Health · cancer source-check · 2026-08-23
Ivermectin and mebendazole cancer Reel: real paper, major caution, and an Expression of Concern
A Facebook Reel from InfoWars says 84% of cancer patients taking ivermectin plus mebendazole had cancer disappear, shrink or stop spreading after six months. The paper it points to is real — but PubMed also links an official Expression of Concern.
Not medical advice: This is a source-check, not a cancer protocol. Do not start, stop, delay or replace oncology care because of a Reel. Do not use animal ivermectin/horse paste or off-label drugs without a licensed clinician.
Captured InfoWars Reel, 119.125 seconds. Facebook metadata title: “Ivermectin & Mebendazole.”
What the Reel claims
The transcript says: “We found that 84% of cancer patients taking ivermectin with mebendazole declared their cancer had completely disappeared, shrunk or stopped spreading after six months.” It also says the study is peer-reviewed/published, gives anecdotal cancer stories, and makes unsupported claims about CIA-suppressed Russian studies.
The paper is real — but flagged
PubMed lists Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort, Nicolas Hulscher et al., Anticancer Research, 2026;46(6):3243–3255, DOI 10.21873/anticanres.18194, PMID 42203321.
The abstract reports 197 patients prescribed ivermectin and mebendazole through a U.S. telemedicine platform, with 122 completing six-month follow-up. It reports an 84.4% Clinical Benefit Ratio, including self-reported no evidence of disease, regression, stable disease and progression categories.
However: PubMed also links an Expression of Concern. That notice says serious concerns were raised about the verifiability and statistical reliability of the dataset and ethical oversight. It also states Anticancer Research does not endorse or condone unvalidated off-label use of medications for unapproved oncology indications.
How to read the 84% number
| What is fair to say | What is not proven |
|---|---|
| A published observational cohort reported a high self-reported clinical-benefit ratio. | It does not prove ivermectin + mebendazole cures cancer. |
| Ivermectin has preclinical anticancer research interest. | Cell/animal findings do not equal proven human treatment. |
| The publication exists and is indexed by PubMed. | Publication does not erase the Expression of Concern. |
Reports included in the updated cancer PDF
- Hulscher et al. 2026 PubMed paper entry.
- Anticancer Research Expression of Concern.
- Springer/Current Oncology Reports 2025 review cautioning that human clinical evidence is limited and large RCTs are missing.
- Gynecologic Oncology Reports 2025 “What’s the data?” and “Hope versus hype.”
- 2020 PMC review on ivermectin’s potential anticancer mechanisms.
- ClinicalTrials.gov NCT05318469 context.
- MedlinePlus/FDA/DailyMed ivermectin safety and label captures.
- Prior PBC NK-cell cancer source-check PDF.
Source package and PDF
Expanded cancer PDF · Source note · Claim table · Reel transcript · Expression of Concern capture · PubMed paper capture
Bottom line: The 84% claim is based on a real, published observational article, but the article is explicitly under an Expression of Concern. Treat it as a lead for research questions, not as a cancer treatment recommendation.